These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals. Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210 [TBL] [Abstract][Full Text] [Related]
4. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. Van Caenegem E; Wierckx K; Taes Y; Dedecker D; Van de Peer F; Toye K; Kaufman JM; T'Sjoen G J Clin Endocrinol Metab; 2012 Jul; 97(7):2503-11. PubMed ID: 22564669 [TBL] [Abstract][Full Text] [Related]
5. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125 [TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Lee H; McGovern K; Finkelstein JS; Smith MR Cancer; 2005 Oct; 104(8):1633-7. PubMed ID: 16116596 [TBL] [Abstract][Full Text] [Related]
7. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949 [TBL] [Abstract][Full Text] [Related]
8. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Lapauw B; Taes Y; Simoens S; Van Caenegem E; Weyers S; Goemaere S; Toye K; Kaufman JM; T'Sjoen GG Bone; 2008 Dec; 43(6):1016-21. PubMed ID: 18835591 [TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and body composition in Thai Precocious Puberty girls treated with GnRH agonist. Wacharasindhu S; Petwijit T; Aroonparkmongkol S; Srivuthana S; Kingpetch K J Med Assoc Thai; 2006 Aug; 89(8):1194-8. PubMed ID: 17048429 [TBL] [Abstract][Full Text] [Related]
10. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752 [TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis]. Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533 [TBL] [Abstract][Full Text] [Related]
12. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065 [TBL] [Abstract][Full Text] [Related]
13. Gender differences in plasma ghrelin and its relations to body composition and bone - an opposite-sex twin study. Makovey J; Naganathan V; Seibel M; Sambrook P Clin Endocrinol (Oxf); 2007 Apr; 66(4):530-7. PubMed ID: 17371471 [TBL] [Abstract][Full Text] [Related]
14. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323 [TBL] [Abstract][Full Text] [Related]
15. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults. Smith KP; Madison CM; Milne NM Pharmacotherapy; 2014 Dec; 34(12):1282-97. PubMed ID: 25220381 [TBL] [Abstract][Full Text] [Related]
16. Add-back therapy in the treatment of endometriosis: the European experience. Edmonds DK Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980 [TBL] [Abstract][Full Text] [Related]
18. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients. Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903 [TBL] [Abstract][Full Text] [Related]
19. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism]. Zhang M; He Y; Cao S Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574 [TBL] [Abstract][Full Text] [Related]
20. Determinants of bone mineral density in older men and women: body composition as mediator. Pluijm SM; Visser M; Smit JH; Popp-Snijders C; Roos JC; Lips P J Bone Miner Res; 2001 Nov; 16(11):2142-51. PubMed ID: 11697812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]